Avita Medical – ReCell receives FDA IDE Compassionate use approval.
ASX release here.
Avita Medical – ReCell containing ambient-stored enzyme launched in United Kingdom and europe
/in Avita Medical, Portfolio CompaniesAustralia, 8 April 2014 – Link here. NORTHRIDGE, Calif., and CAMBRIDGE, United Kingdom, 8 April 2014 – Regenerative medicine company Avita Medical Limited “Avita Medical” (ASX:AVH), (OTCQX:AVMXY) is pleased to advise that it has developed and released to market a new version of ReCell® ‘Spray‐on Skin®’ that no longer requires refrigeration. This greatly improves the commercial and […]
Nexvet shares promise of new treatments for chronic illness in companion animals with BSAVA Congress 2014
/in Pharmamark, Portfolio CompaniesLink here. BIRMINGHAM, United Kingdom –‐ April 3, 2014 – Nexvet Biopharma, a leading veterinary biologic drug developer, today announced that its Chief Scientific Officer, Professor David Gearing, will be presenting at the British Small Animal Veterinary Association (BSAVA) Congress 2014. The BSAVA Congress runs from April 3 – 6 and is one of Europe’s largest […]
SeaDragon Investor Update March 2014
/in Portfolio Companies, SeaDragonSEA:NZX MARKET UPDATE 1 April 2014 SeaDragon Investor Update March 2014 (Link here). SeaDragon, Australasia’s largest refiner and blender of high-quality, internationally certified concentrated fish oils and fractions, including Omega-3 oils, today releases its investor update. The update includes: • an update on trading; • significant growth in squalene business following the execution of a raw […]
SeaDragon signs significant raw material supply contract
/in Portfolio Companies, SeaDragon10 March 2014. Link here. SeaDragon signs significant raw material supply contract Agreement overcomes historical supply constraints Australasia’s largest fish-oil refiner SeaDragon (NZX: SEA) announces a new raw material supply agreement has been signed that will underpin its Nelson-based squalene manufacturing operations, and enable the business to seek new market opportunities in the pharmaceutical and cosmetic […]
Avita Medical December 2013 Half Year Report
/in Avita Medical, Portfolio CompaniesASX Announcement (link here). 28 February 2014.
AmpliPhi to Present at Upcoming Healthcare Conferences
/in Armata Pharmaceuticals, Portfolio CompaniesFebruary 26, 2014. Link here. Cowen and Company 34th Annual Healthcare Conference 26th Annual ROTH Conference AmpliPhi BioSciences Corporation (OTCBB: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that President and CEO, Philip Young will be presenting at the Cowen and Company 34^th Annual Healthcare Conference at the Boston Marriott […]
Bioxyne Ltd completes sale of HI-164OV program to Mariposa Health Ltd
/in Portfolio CompaniesLink to press release here.
ASX BIOTECH STOCKS SURGE 54% IN 2013
/in BioSciences Managers7 January 2014: Analysis from leading healthcare fund manager BioScience Managers has highlighted the outstanding year for biotech stocks on the ASX in 2013 with an average gain of 53.6%* across the sector. These findings compare with the All Ordinaries index that increased by 14.7% over 2013 and theS&P/ASX 200 Health Care Index which increased 23.5% […]